Item 8.01 Other Events.

On November 21, 2008, the shareholders of Barr Pharmaceuticals, Inc. voted to adopt the Agreement and Plan of Merger, dated July 17, 2008, by and among Barr Pharmaceuticals, Inc. ("Barr"), Teva Pharmaceutical Industries Limited ("Teva") and a wholly owned subsidiary of Teva, Boron Acquisition Corp. as amended, under which Barr will merge with and into a wholly owned subsidiary of Teva Pharmaceuticals USA (also a wholly owned subsidiary of Teva). The merger is expected to be completed in December, 2008, subject to the satisfaction or waiver of the conditions set forth in the Agreement and Plan of Merger, including obtaining approval of the merger from U.S. and E.U. anti-trust authorities. Under the terms of the merger agreement, holders of Barr common stock will receive $39.90 in cash plus 0.6272 ordinary shares of Teva (in the form of American Depositary Shares) for each share of Barr common stock issued and outstanding immediately before the effective time of the merger. Item 9.01 Financial Statement and Exhibits

(d) Exhibits

99.1 Barr Pharmaceuticals, Inc. November 21, 2008 press release.

---